On Biotech: Aratana primes puppy pharma pipeline

Even as Aratana Therapeutics ramps up marketing for its current portfolio, the Leawood company continues to move new treatments for Fido through its development pipeline. The star of the company’s May 9 investor call was Galliprant, a canine osteoarthritis treatment on its way to becoming a blockbuster. But Aratana’s plans include another treatment for more severe osteoarthritis cases, in addition to an immunotherapy treatment for bone cancer. “Lately, a lot of the focus at Aratana has been…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news